Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 186Head & Neck 28Gastrointestinal 27Breast 24CNS 21Genitourinary 18Sarcoma 11Other solid neoplasm 8Tumor-Agnostic 6Gynecologic 6Endocrine 4Dermatologic 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Skin Neoplasms 3

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Gefitinib × Dermatologic × Clear all
NCT00126555 2019-08-30

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 12 charts
Dermatologic

Skin Neoplasms

NCT00054691 2015-03-13

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

M.D. Anderson Cancer Center

Phase 2 Completed
40 enrolled 6 charts
Dermatologic

Skin Neoplasms

NCT00423397 2013-12-19

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
16 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡